Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Equity Average (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Equity Average for 8 consecutive years, with $976.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 27.81% to $976.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $976.6 million, a 27.81% decrease, with the full-year FY2024 number at $1.1 billion, up 9.03% from a year prior.
  • Equity Average was $976.6 million for Q3 2025 at Denali Therapeutics, down from $1.1 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.4 billion in Q2 2024 to a low of $847.9 million in Q3 2022.
  • A 5-year average of $1.1 billion and a median of $1.1 billion in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 139.94% in 2021, then dropped 27.81% in 2025.
  • Denali Therapeutics' Equity Average stood at $987.3 million in 2021, then fell by 6.12% to $926.9 million in 2022, then rose by 15.94% to $1.1 billion in 2023, then rose by 18.56% to $1.3 billion in 2024, then fell by 23.35% to $976.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Equity Average are $976.6 million (Q3 2025), $1.1 billion (Q2 2025), and $1.2 billion (Q1 2025).